Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 17 de 17
Filter
1.
Blood ; 131(13): 1456-1463, 2018 03 29.
Article in English | MEDLINE | ID: mdl-29437590

ABSTRACT

We tested baseline positron emission tomography (PET)/computed tomography (CT) as a measure of total tumor burden to better identify high-risk patients with early-stage Hodgkin lymphoma (HL). Patients with stage I-II HL enrolled in the standard arm (combined modality treatment) of the H10 trial (NCT00433433) with available baseline PET and interim PET (iPET2) after 2 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine were included. Total metabolic tumor volume (TMTV) was measured on baseline PET. iPET2 findings were reported negative (DS1-3) or positive (DS4-5) with the Deauville scale (DS). The prognostic value of TMTV was evaluated and compared with baseline characteristics, staging classifications, and iPET2. A total of 258 patients were eligible: 101 favorable and 157 unfavorable. The median follow-up was 55 months, with 27 progression-free survival (PFS) and 12 overall survival (OS) events. TMTV was a prognosticator of PFS (P < .0001) and OS (P = .0001), with 86% and 84% specificity, respectively. Five-year PFS and OS were 71% and 83% in the high-TMTV (>147 cm3) group (n = 46), respectively, vs 92% and 98% in the low-TMTV group (≤147 cm3). In multivariable analysis including iPET2, TMTV was the only baseline prognosticator compared with the current staging systems proposed by the European Organization for Research and Treatment of Cancer/Groupe d'Etude des Lymphomes de l'Adulte, German Hodgkin Study Group, or National Comprehensive Cancer Network. TMTV and iPET2 were independently prognostic and, combined, identified 4 risk groups: low (TMTV≤147+DS1-3; 5-year PFS, 95%), low-intermediate (TMTV>147+DS1-3; 5-year PFS, 81.6%), high-intermediate (TMTV≤147+DS4-5; 5-year PFS, 50%), and high (TMTV>147+DS4-5; 5-year PFS, 25%). TMTV improves baseline risk stratification of patients with early-stage HL compared with current staging systems and the predictive value of early PET response as well.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Hodgkin Disease , Adolescent , Adult , Aged , Bleomycin/administration & dosage , Dacarbazine/administration & dosage , Disease-Free Survival , Doxorubicin/administration & dosage , Female , Follow-Up Studies , Hodgkin Disease/drug therapy , Hodgkin Disease/metabolism , Hodgkin Disease/mortality , Hodgkin Disease/pathology , Humans , Male , Middle Aged , Neoplasm Staging , Survival Rate , Vinblastine/administration & dosage
2.
Eur J Nucl Med Mol Imaging ; 44(2): 267-283, 2017 Feb.
Article in English | MEDLINE | ID: mdl-27909770

ABSTRACT

PURPOSE: To investigate changes in sympathetic activity, perfusion, and left ventricular (LV) functionality in takotsubo cardiomyopathy (TTC) patients from onset (T0) to post-onset conditions at 1 month (T1), 1-2 years (T2, T3). METHODS: Twenty-two patients (70 ± 11 years) underwent serial gated single photon emission tomography (G-SPECT) studies with 123I-mIBG and 99mTc-Sestamibi. Statistics were performed using ANOVA/Sheffé post-hoc, correlation test, and receiver operating characteristic (ROC) curve analysis (p < 0.05). RESULTS: Patients presented at T0 with LV ballooning and reduced early-late mIBG uptake (95%, 100%), left ventricular ejection fraction (LVEF)G-SPECT (86%) and perfusion (77 %). Adrenergic dysfunction was greater in apex, it overlaps with contractile impairment, and both were more severe than perfusion defect. During follow-up, LVEFG-SPECT, contractility, and perfusion were normal, while 82% and 90% of patients at T1 and 50% at T2 and T3 continued to show a reduced apical early-late mIBG distribution. These patients presented at T0-T1 with greater impairment of adrenergic function, contractility, and perfusion. A relationship was present within innervation and both perfusion and contractile parameters at T0 and T1, and between the extent of adrenergic defect at T3 and both the defect extent and age at T0 (cut-off point 42.5%, 72 years). CONCLUSION: Outcome for TTC is not limited to a reversible contractile and perfusion abnormalities, but it includes residual adrenergic dysfunction, depending on the level of adrenergic impairment and age of patients at onset. The number of patients, as well as degree of perfusion abnormalities were found to be higher than those previously reported possibly depending on the time-interval between hospital admission and perfusion scan.


Subject(s)
Autonomic Nervous System Diseases/diagnostic imaging , Gated Blood-Pool Imaging/methods , Myocardial Perfusion Imaging/methods , Stress, Psychological/diagnostic imaging , Takotsubo Cardiomyopathy/diagnostic imaging , Ventricular Dysfunction, Left/diagnostic imaging , Aged , Aged, 80 and over , Autonomic Nervous System Diseases/complications , Disease Progression , Echocardiography , Female , Follow-Up Studies , Humans , Longitudinal Studies , Male , Middle Aged , Stress, Psychological/complications , Takotsubo Cardiomyopathy/complications , Ventricular Dysfunction, Left/etiology
3.
Curr Radiopharm ; 9(2): 150-9, 2016.
Article in English | MEDLINE | ID: mdl-27593255

ABSTRACT

PURPOSE: To assess changes in social and neuro-cognition and regional cerebral blood flow (rCBF) in schizophrenic patients with psychotic syndrome treated with Social Skill Training (SST). METHODS: 17 patients underwent two high resolution rCBF SPECT at rest before and after a one-year treatment with SST. Patients were assessed using a neuropsychological evaluation (W.A.I.S.-R, T.M.T, Verbal Fluency, W.C.S.T.). SPM8 was used to investigate rCBF changes from the pre- to the post-SST condition and the relationship between rCBF and clinical scores used as covariates of interest. RESULTS: All patients presented with an improvement in social perception, ability to deal with abstract social conventions, rules and judgments about people (Comprehension and Picture Completion sub-tests) and some neuro-cognitive functions sustaining the process of socially relevant information. The main effect of SST was to produce rCBF increases in precuneus, PCC, superior parietal lobules, PMC, pre-SMA, precentral gyrus, dmPFC, dlPFC, vmPFC, OFC (p<0.0001 uncorrected). The SPM analysis showed that Comprehension was supported by PMC, dmPFC, OFC and vmPFC, while the Picture Completion was supported by PMC and dmPFC (p<0.0001). CONCLUSION: SST in schizophrenic patients improves resting neural activity in cortical areas of the amigdala-based and non-amygdala networks of social brain, including dmPFC and vmPFC, and dlPFC, which are known to be part of default mode and task-positive networks and to be implicated in schizophrenia.


Subject(s)
Psychotic Disorders/rehabilitation , Schizophrenia/rehabilitation , Social Skills , Adult , Brain/blood supply , Brain/diagnostic imaging , Cerebrovascular Circulation , Cognition , Female , Humans , Male , Middle Aged , Neuropsychological Tests , Psychotic Disorders/diagnostic imaging , Psychotic Disorders/physiopathology , Schizophrenia/diagnostic imaging , Schizophrenia/physiopathology , Tomography, Emission-Computed, Single-Photon
4.
J Clin Oncol ; 34(12): 1376-85, 2016 Apr 20.
Article in English | MEDLINE | ID: mdl-26884559

ABSTRACT

PURPOSE: The clinical impact of positron emission tomography (PET) evaluation performed early during first-line therapy in patients with advanced-stage Hodgkin lymphoma, in terms of providing a rationale to shift patients who respond poorly onto a more intensive regimen (PET response-adapted therapy), remains to be confirmed. PATIENTS AND METHODS: The phase II part of the multicenter HD0801 study involved 519 patients with advanced-stage de novo Hodgkin lymphoma who received an initial treatment with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) and who underwent an early ifosfamide-containing salvage treatment followed by stem-cell transplantation if they showed a positive PET evaluation after two cycles of chemotherapy (PET2). The primary end point was 2-year progression-free survival calculated for both PET2-negative patients (who completed a full six cycles of ABVD treatment) and PET2-positive patients. Overall survival was a secondary end point. RESULTS: In all, 103 of the 512 evaluable patients were PET2 positive. Among them, 81 received the scheduled salvage regimen with transplantation, 15 remained on ABVD (physician's decision, mostly because of minimally positive PET2), five received an alternative treatment, and two were excluded because of diagnostic error. On intention-to-treat analysis, the 2-year progression-free survival was 76% for PET2-positive patients (regardless of the salvage treatment they received) and 81% for PET2-negative patients. CONCLUSION: Patients with advanced-stage Hodgkin lymphoma for whom treatment was at high risk of failing appear to benefit from early treatment intensification with autologous transplantation, as indicated by the possibility of successful salvage treatment in more than 70% of PET2-positive patients through obtaining the same 2-year progression-free survival as the PET2-negative subgroup.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Drug Substitution , Hodgkin Disease/therapy , Positron-Emission Tomography , Stem Cell Transplantation , Adolescent , Adult , Aged , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Disease Progression , Disease-Free Survival , Female , Hodgkin Disease/diagnostic imaging , Hodgkin Disease/mortality , Humans , Italy , Kaplan-Meier Estimate , Male , Middle Aged , Neoplasm Staging , Patient Selection , Predictive Value of Tests , Risk Assessment , Risk Factors , Salvage Therapy , Stem Cell Transplantation/adverse effects , Stem Cell Transplantation/mortality , Time Factors , Treatment Outcome , Young Adult
5.
Am J Hematol ; 90(6): 499-503, 2015 Jun.
Article in English | MEDLINE | ID: mdl-25720750

ABSTRACT

This retrospective study included 246 patients with a new diagnosis of Hodgkin Lymphoma (HL) with a localized-stage (IA-IIA), consecutively admitted from January 2002 to December 2008, by twelve Italian hematological centers on behalf of Fondazione Italiana Linfomi (FIL). Patients were staged at baseline and after two cycles of chemotherapy with PET. All patients were treated with four cycles of ABVD followed by involved-field radiotherapy. No treatment change, based on PET-2 results was allowed. Endpoint of the study was the predictive role of PET-2 on 2-y failure-free survival (FFS). PET-2 was positive in 36 patients (15%) and negative in 210. After a mean follow-up of 46 (3-105) months 19/36 PET-2 positive patients progressed or relapsed and 17 achieved and maintained a CCR. The positive and negative predictive value of a PET2 was 53% and 95%, respectively. The sensibility, specificity and accuracy of PET2 were 65.5%, 92% and 89%, respectively. PET-2 positive scans were centrally reviewed according to the recently defined Deauville Criteria. Upon review the PPV and NPV was 73% and 96% overall. Factors with prognostic significance for progression in univariate analysis were a positive PET-2 (P = 0.000) and the presence of bulky disease (P < 0.01). In a multivariate analysis the only factor that affected negatively FFS was a positive PET-2 (P = 0.000). This study confirms that interim-PET could be considered a prognostic test also in early stage HL, but is unlikely to be a factor that will justify the change of therapeutical approach.


Subject(s)
Hodgkin Disease/diagnostic imaging , Hodgkin Disease/therapy , Positron-Emission Tomography , Adolescent , Adult , Aged , Disease-Free Survival , Female , Follow-Up Studies , Hodgkin Disease/diagnosis , Hodgkin Disease/pathology , Humans , Male , Middle Aged , Neoplasm Staging , Predictive Value of Tests , Radiography , Survival Rate
6.
Surgery ; 155(3): 529-40, 2014 Mar.
Article in English | MEDLINE | ID: mdl-24230962

ABSTRACT

BACKGROUND: Our aim was to perform a meta-analysis of high-quality published trials, randomized and observational, comparing total thyroidectomy (TT) and bilateral subtotal thyroidectomy (ST) for Graves' disease. METHODS: All studies published from 1970 to August 2012 were identified. All randomized controlled trials (RCTs) were included. Selection of high-quality, nonrandomized comparative studies (NRCTs) was based on a validated tool (Methodological Index for Nonrandomized Studies). Recurrent hyperthyroidism during follow-up, progression of ophthalmopathy, postoperative temporary and permanent hypoparathyroidism, and permanent recurrent laryngeal nerve (RLN) palsy were compared using odds ratios (ORs). RESULTS: Twenty-three studies were included (4 RCTs and 19 NRCTs) compromising 3,242 patients (1,665 TT, 1,577 ST). TT was associated with a decrease in recurrent hyperthyroidism (P < .00001; OR, 0.10; 95% confidence interval [CI], 0.06-0.18), but with an increase in both temporary (P < .00001; OR, 2.70; 95% CI, 2.04-3.56) and permanent hypoparathyroidism (P = .005; OR, 2.91; 95% CI, 1.59-5.32). Progression of ophthalmopathy (P = .76; OR, 0.90; 95% CI, 0.48-1.71) and permanent RLN palsy (P = .82; OR, 0.91; 95% CI, 0.41-2.02) were similar. CONCLUSION: TT offers a better chance of cure of hyperthyroidism than bilateral ST and can be accomplished safely with only a small increase in temporary and permanent hypoparathyroidism.


Subject(s)
Graves Disease/surgery , Thyroidectomy/methods , Humans , Models, Statistical , Treatment Outcome
7.
Eur J Nucl Med Mol Imaging ; 39(1): 4-12, 2012 Jan.
Article in English | MEDLINE | ID: mdl-21894546

ABSTRACT

PURPOSE: The use of early (interim) PET restaging during first-line therapy of Hodgkin's lymphoma (HL) in clinical practice has considerably increased because of its ability to provide early recognition of treatment failure allowing patients to be transferred to more intensive treatment regimens. METHODS: Between June 1997 and June 2009, 304 patients with newly diagnosed HL (147 early stage and 157 advanced stage) were treated with the ABVD regimen at two Italian institutions. Patients underwent PET staging and restaging at baseline, after two cycles of therapy and at the end of the treatment. RESULTS: Of the 304 patients, 53 showed a positive interim PET scan and of these only 13 (24.5%) achieved continuous complete remission (CCR), whereas 251 patients showed a negative PET scan and of these 231 (92%) achieved CCR. Comparison between interim PET-positive and interim PET-negative patients indicated a significant association between PET findings and 9-year progression-free survival and 9-year overall survival, with a median follow-up of 31 months. Among the early-stage patients, 19 had a positive interim PET scan and only 4 (21%) achieved CCR; among the 128 patients with a negative interim PET scan, 122 (97.6%) achieved CCR. Among the advanced-stage patients, 34 showed a persistently positive PET scan with only 9 (26.4%) achieving CCR, whereas 123 showed a negative interim PET scan with 109 (88.6%) achieving CCR. CONCLUSION: Our results demonstrate the role of an early PET scan as a significant step forward in the management of patients with early-stage or advanced-stage HL.


Subject(s)
Fluorodeoxyglucose F18 , Hodgkin Disease/diagnostic imaging , Positron-Emission Tomography , Adolescent , Adult , Aged , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Bleomycin/therapeutic use , Dacarbazine/therapeutic use , Doxorubicin/therapeutic use , Female , Hodgkin Disease/drug therapy , Hodgkin Disease/pathology , Humans , Male , Middle Aged , Neoplasm Staging , Prognosis , Retrospective Studies , Time Factors , Vinblastine/therapeutic use , Young Adult
8.
J Cell Physiol ; 227(4): 1663-9, 2012 Apr.
Article in English | MEDLINE | ID: mdl-21678422

ABSTRACT

Positron emission tomography (PET) is an imaging technique that provides direct measurements of receptor binding in neurons. The present study was performed to find reasons for the common observation of rapid metabolism of receptor radioligands during time of a brain PET scan. To this aim, the 1-h phase during which imaging-data are acquired was evaluated by using a pharmacokinetic approach. The values of half-lives, volumes of distribution, and dilution calculated for a set of metabolite corrected plasma curves of D2-receptor radioligand [(11)C]raclopride (PETc) during 50 min after radioligand injection in tracer dose were compared with the reference values obtained from a set of plasma curves (REFc) during 30 h after i.v. infusion of unlabelled raclopride in pharmacological doses. We found that the half-life of PETc correspond to the distribution half-life of REFc. Accordingly, the distribution volume during the terminal phase of PETc (13.6 ± 10.8 L) was significantly lower than that during the terminal phase (82.2 ± 30.5 L) and at steady state (59.4 ± 20 L) for REFc, and the dilution of raclopride in body for PETc at 50 min was 38 L, whereas it was 1015 L for REFc at 30 h. The [(11)C]raclopride in plasma at 50 min was higher (10% of dose) than the value for unlabelled raclopride at 30 h (4%). We concluded that the kinetic behavior of the radiolabelled drug [(11)C]raclopride during the 1 h time of a PET corresponds to the distribution phase. The high percentage of [(11)C]raclopride in plasma during this phase is a likely reason for the observed rapid radioligand metabolism.


Subject(s)
Raclopride/pharmacokinetics , Adult , Aged , Antipsychotic Agents/administration & dosage , Antipsychotic Agents/blood , Antipsychotic Agents/pharmacokinetics , Brain/diagnostic imaging , Brain/metabolism , Case-Control Studies , Dopamine Antagonists/administration & dosage , Dopamine Antagonists/blood , Dopamine Antagonists/pharmacokinetics , Female , Half-Life , Humans , Ligands , Male , Positron-Emission Tomography , Raclopride/administration & dosage , Raclopride/blood , Radiopharmaceuticals/administration & dosage , Radiopharmaceuticals/blood , Radiopharmaceuticals/pharmacokinetics , Receptors, Dopamine D2/metabolism , Schizophrenia/blood , Schizophrenia/diagnostic imaging , Schizophrenia/drug therapy , Young Adult
9.
J Nucl Cardiol ; 17(5): 825-30, 2010 Oct.
Article in English | MEDLINE | ID: mdl-20521138

ABSTRACT

BACKGROUND: Because of persistent stunning, post-treatment functional abnormalities could identify the initial risk area. The study aims to detect myocardial salvage using post-revascularization gated SPECT in acute myocardial infarction (AMI) treated by reperfusion therapy. METHODS: In 36 AMI patients, we performed a first gated SPECT injecting (99m)Tc-sestamibi before primary percutaneous coronary intervention (PCI), and a second 5 days later. The salvage index defined by the two perfusion images was compared with the value obtained by subtracting in the second gated SPECT the extent of perfusion defect from the extent of wall thickening abnormalities. RESULTS: The wall thickening salvage index correlated with the reference perfusion salvage index (Spearman's ρ = .92, P < .0001), with a 95% limit of agreement = ±.25. The agreement between the classifications in salvage index tertiles of the reference and of the wall thickening salvage index was good (kappa = .75). All patients with optimal PCI result and 18/24 of those with intermediate or poor outcome were correctly classified. CONCLUSIONS: Comparing function and perfusion in a single post-PCI (99m)Tc-sestamibi gated SPECT it is possible to estimate myocardial salvage. This could have useful implications in studies comparing different treatment strategies for AMI.


Subject(s)
Coronary Circulation , Gated Blood-Pool Imaging/methods , Heart/physiopathology , Myocardial Infarction/diagnostic imaging , Tomography, Emission-Computed, Single-Photon/methods , Acute Disease , Aged , Angioplasty, Balloon, Coronary , Feasibility Studies , Female , Humans , Male , Middle Aged , Myocardial Infarction/physiopathology , Myocardial Reperfusion
10.
Eur J Nucl Med Mol Imaging ; 37(1): 12-22, 2010 Jan.
Article in English | MEDLINE | ID: mdl-19582450

ABSTRACT

PURPOSE: The aim of this study was to investigate the predictive potential of pre-operative regional cerebral blood flow (rCBF) in the pre-supplementary motor area (pre-SMA) and clinical factors in Parkinson's disease (PD) patients treated with subthalamic nucleus (STN) stimulation. METHODS: Ten patients underwent rCBF SPECT and motor Unified Parkinson's Disease Rating Scale (UPDRS) pre- and post-operatively during stimulation at 5 and 42 months. Statistical parametric mapping (SPM) was used to extract rCBF values in the pre-SMA because it is related with motor improvement. Post-operative outcomes included motor response to stimulation and percent improvement in UPDRS. Pre-operative predictors were explored by correlation test, linear regression and multivariate analyses. RESULTS: Higher pre-operative rCBF in the pre-SMA and younger age were associated with favourable outcomes at 5 and 42 months. Pre-operative rCBF results were significantly associated with baseline clinical factors. CONCLUSION: This study shows that PD patients with younger age have higher rCBF values in the pre-SMA and better outcome, thus giving the rationale to the hypothesis that STN stimulation could be considered early in the course of disease.


Subject(s)
Electric Stimulation Therapy/methods , Motor Cortex/diagnostic imaging , Parkinson Disease/diagnostic imaging , Parkinson Disease/therapy , Subthalamic Nucleus , Feasibility Studies , Female , Humans , Male , Middle Aged , Prognosis , Radionuclide Imaging , Treatment Outcome
12.
Ann Hematol ; 86(12): 897-903, 2007 Dec.
Article in English | MEDLINE | ID: mdl-17701410

ABSTRACT

In this prospective multicentric study, we investigated the contribution of positron emission tomography (PET) scanning to the staging of Hodgkin's lymphoma (HL) by computed tomography (CT) and attempted to determine whether it has any impact on therapeutic approach. One hundred eighty six consecutive patients with HL from six Italian centers were enrolled in this study. They were staged with conventional methods; 2-[fluorine-18]fluoro-2-deoxy-D: -glucose PET scanning were prospectively compared to CT. CT and FDG-PET stages were concordant in 156 patients (84%) and discordant in 30 patients (16%). PET stage in comparison to CT stage was higher in 27 patients (14%) and lower in 3 patients (1%). The programmed treatment strategy was modified in 11 out of 30 patients (37%) after the definition of final stage. If we considered the 123 CT staged patients with localized stage, ten patients (8%) with a change of stage from localized to advanced after PET evaluation were treated with different strategy. FDG-PET was shown to be a relevant, non-invasive method that supplements conventional procedures and should therefore be used routinely to stage HL, particularly in early stage patients, where a change in stage may modify disease management.


Subject(s)
Hodgkin Disease/diagnostic imaging , Neoplasm Staging/methods , Positron-Emission Tomography , Adolescent , Adult , Aged , Bone Marrow/diagnostic imaging , Disease Management , Female , Fluorine Radioisotopes , Fluorodeoxyglucose F18 , Humans , Italy , Male , Middle Aged , Predictive Value of Tests , Prospective Studies , Radiopharmaceuticals , Tomography, X-Ray Computed
13.
Eur J Nucl Med Mol Imaging ; 34(10): 1646-57, 2007 Oct.
Article in English | MEDLINE | ID: mdl-17479265

ABSTRACT

PURPOSE: The aim of this follow-up study was to assess persistent motor and regional cerebral blood flow (rCBF) changes in patients with Parkinson's disease (PD) treated with high-frequency deep brain stimulation (DBS) of the subthalamic nucleus (STN). METHODS: Ten PD patients with STN-DBS underwent three rCBF SPECT studies at rest, once preoperatively in the off-drug condition (T(0)), and twice postoperatively in the off-drug/off-stimulation conditions at 5 +/- 2 (T(1)) and 42 +/- 7 months (T(2)). Patients were assessed using the UPDRS, H&Y and S&E scales. SPM was used to investigate baseline rCBF changes from the preoperative condition to the postoperative conditions and the relationship between rCBF and UPDRS scores used as covariate of interest. RESULTS: Parkinsonian patients showed a clinical improvement which was significant only on follow-up at 42 months. The main effect of treatment from T(0) to T(1) was to produce baseline rCBF increases in the pre-supplementary motor area (pre-SMA), premotor cortex and somatosensory association cortex. From T(1) to T(2) a further baseline rCBF increase was detected in the pre-SMA (p < 0.0001). A correlation was detected between the slight improvement in motor scores and the rCBF increase in the pre-SMA (p < 0.0001), which is known to play a crucial role in clinical progression. CONCLUSION: Our study suggests the presence of adaptive functional changes in the human brain of PD patients treated with long-term STN-DBS. Such adaptive processes seem to occur in the pre-SMA and to play only a slightly beneficial role in terms of functional compensation of motor impairment.


Subject(s)
Brain Mapping/methods , Deep Brain Stimulation/methods , Parkinson Disease/physiopathology , Parkinson Disease/therapy , Subthalamic Nucleus/physiopathology , Tomography, Emission-Computed, Single-Photon/methods , Adaptation, Physiological , Cerebrovascular Circulation , Female , Follow-Up Studies , Humans , Male , Middle Aged , Parkinson Disease/diagnostic imaging , Subthalamic Nucleus/blood supply , Subthalamic Nucleus/diagnostic imaging , Treatment Outcome
14.
Haematologica ; 91(4): 475-81, 2006 Apr.
Article in English | MEDLINE | ID: mdl-16585014

ABSTRACT

BACKGROUND AND OBJECTIVES: We explored the predictive value on therapy outcome of an early evaluation of treatment response by 18F-fluorodeoxyglucose position emission tomography (18F-FDG-PET) scan performed after two courses of conventional standard-dose chemotherapy in advanced-stage Hodgkin's disease. DESIGN AND METHODS: One hundred and eight patients with newly-diagnosed Hodgkin's disease in stage IIA with adverse prognostic factors, or in stage IIB through IVB, were re-staged with FDG-PET after two cycles of ABVD (PET-2). The end-point of the study was the predictive value of PET-2 on 2-year progression-free survival and 2-year failure-free survival. No treatment variation based only on PET-2 results was allowed. RESULTS: Eighty-eight patients attained complete remission (CR) while 20 showed disease progression during therapy or within 6 months after having reached CR; one patient relapsed. PET-2 was positive in 20 patients: 17 progressed during therapy, one relapsed and two remained in CR. By contrast, 85/88 (97%) patients with a negative PET-2 remained in CR; three progressed or relapsed early after the end of the chemotherapy. Thus, the positive predictive value of a PET-2 was 90% and the negative predictive value was 97%. The sensitivity, specificity and overall accuracy of PET-2 were 86%, 98% and 95%, respectively. The 2-year probability of failure-free survival for PET-2 negative and for PET-2 positive patients was 96% and 6%, respectively (log rank test = 116.7, p < 0.01). INTERPRETATION AND CONCLUSIONS: 18F-FDG-PET scan performed after two courses of conventional standard-dose chemotherapy in advanced-stage Hodgkin's disease was able to predict treatment outcome in 103/108 (95%) of the patients.


Subject(s)
Hodgkin Disease/diagnosis , Hodgkin Disease/therapy , Positron-Emission Tomography/methods , Predictive Value of Tests , Adolescent , Adult , Aged , Disease-Free Survival , Female , Fluorodeoxyglucose F18 , Humans , Male , Middle Aged , Neoplasm Staging/methods , Positron-Emission Tomography/standards , Treatment Outcome
15.
Oncol Rep ; 14(5): 1209-14, 2005 Nov.
Article in English | MEDLINE | ID: mdl-16211287

ABSTRACT

In patients with Hodgkin's lymphoma (HL) at the end of first line therapy an accurate imaging technique with high prognostic value is needed to assess response to treatment and predict those patients who will suffer disease relapse. This technique and its results permit the quick initiation of a second line therapy in patients suffering from a progressive disease or those unresponsive to treatment avoid over-treatment of patients in complete remission or those having a non-active residual disease. We included a (18)FDG-positron emission tomography (PET) scan to the diagnostic set-up to investigate 28 patients following the end of their treatment. Fifteen patients out of the 28 (54%) had positive CT scans while 13 (46%) had negative ones. Eleven patients out of the 15 CT positive (73%) had negative PET scans and no relapse. The remaining four patients (27%) had positive PET scans with only one relapse (25%). With respect to the 13 patients who had negative CT scans, 9 patients (69%) had negative PET scans and no relapse. The remaining 4 patients (31%) had positive PET scans with 3 relapse cases (75%). In our final assessment after a median follow-up period of 45 months, starting from PET execution to the last follow-up, overall sensitivity of the CT and the PET were 25 and 100% respectively, specificity 42 and 83% respectively, positive predictive value (PPV) 7 and 50% respectively, negative predictive value (NPV) 77 and 100% respectively, and accuracy 39 and 86% respectively. In our experience, FDG-PET performed in patients after induction therapy appears to offer important additional information: FDG-PET results are predictors of prognosis giving 100% DFS in PET negative patients and 54% DSF in PET positive patients.


Subject(s)
Hodgkin Disease/diagnostic imaging , Positron-Emission Tomography , Adolescent , Adult , Aged , Female , Fluorodeoxyglucose F18 , Hodgkin Disease/drug therapy , Humans , Male , Middle Aged , Neoplasm, Residual , Predictive Value of Tests , Prognosis , Radiopharmaceuticals , Sensitivity and Specificity , Tomography, X-Ray Computed
16.
Leuk Lymphoma ; 44(11): 2015-8, 2003 Nov.
Article in English | MEDLINE | ID: mdl-14738158

ABSTRACT

We report the case of a 31-year-old man with anaplastic large-cell lymphoma successfully treated with chemotherapy who showed mediastinal widening 5 months after autologous stem-cell transplantation. CT scan and PET evaluations were consistent with the diagnosis of benign thymic hyperplasia. Because of the rapid and aggressive course of this type of lymphoma, and the progressive widening of the mass at CT scan, we performed a mediastinal biopsy that confirmed these findings, showing normal thymic tissue. This is the first case of benign thymic hyperplasia defined with FDG-PET and confirmed by histologic evaluation.


Subject(s)
Carcinoma/therapy , Lymphoma, Non-Hodgkin/therapy , Peripheral Blood Stem Cell Transplantation/adverse effects , Thymus Hyperplasia/etiology , Tomography, Emission-Computed/methods , Adult , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carcinoma/complications , Fluorine Radioisotopes , Fluorodeoxyglucose F18 , Humans , Lymphoma, Non-Hodgkin/complications , Male , Radiopharmaceuticals , Thymus Hyperplasia/diagnostic imaging , Thymus Hyperplasia/pathology , Transplantation, Autologous
SELECTION OF CITATIONS
SEARCH DETAIL
...